Fibrinolytic Deficit in Patients With Acute PE

Status unconfirmed

Conditions studied: Acute Pulmonary Embolism, Fibrinolytic Deficit

In brief

Fibrinolysis is the body's process that prevents blood clots. The investigators hypothesize that patients presenting with acute pulmonary embolism (PE) or blood clots in the lungs differ in their fibrinolytic deficit phenotype. The investigators aim to use biomarkers directly involved in endogenous fibrinolytic cascade including PAI-1, Alpha-2-Antiplasmin (A2A), TAFI, D-dimer, and Fibrinogen to phenotypically characterize patients presenting with acute PE and to correlate these biomarkers with clinical, echocardiographic, computed tomography (CT), and functional status outcomes.

Key facts

Study ID

NCT04480892

Run by

Loyola University

People needed

100

Starts

2020-08-01

Expected to finish

2024-12-01

Last updated by the study team

2020-07-22

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients age 18 - 90 years
• Patients suffering an acute PE
• Blood collected for clinical evaluation of PE

You may not qualify if…

• Blood not collected or not sufficient quantity/quality

Where it is running

• Loyola University Medical Center — Maywood, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.